Direct Thrombin and Factor Xa Inhibition for Stroke Prevention in Patients With Atrial Fibrillation

References

• . Go AS, Hylek EM, Phillips KA, . Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375
   PubMed Web of Science ®Google Scholar
• . Crandall MA, Bradley DJ, Packer DL, Asirvatham SJ. Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. Mayo Clin Proc. 2009;84(7):643–662
   Google Scholar
• . Lloyd-Jones D, Adams RJ, Brown TM, . Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948–954
   PubMedGoogle Scholar
• . Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008;92(1):17–40, ix
   PubMed Web of Science ®Google Scholar
• . Bajpai A, Savelieva I, Camm AJ. Epidemiology and economic burden of atrial fibrillation. US Cardiol. 2007;4(1):14–17
   Google Scholar
• . Miyasaka Y, Barnes ME, Gersh BJ, . Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125
   PubMed Web of Science ®Google Scholar
• . Lloyd-Jones DM, Wang TJ, Leip EP, . Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–1046
   PubMed Web of Science ®Google Scholar
• . Go AS. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol. 2005;14(2):56–61
   Google Scholar
• . Fuster V, Rydén LE, Cannom DS, ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines, European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257–e354
   PubMed Web of Science ®Google Scholar
• . Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–844
   PubMed Web of Science ®Google Scholar
• . Thanassoulis G, Massaro JM, O'Donnell CJ, . Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol. 2010;3(4):345–350
   PubMed Web of Science ®Google Scholar
• . Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28(10):973–977
   PubMed Web of Science ®Google Scholar
• . Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359–364
   PubMed Web of Science ®Google Scholar
• . Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003;22(2):118–123
   PubMedGoogle Scholar
• . Fang MC, Singer DE, Chang Y, . Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112(12):1687–1691
   PubMed Web of Science ®Google Scholar
• . Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10( suppl 14):S451–S458
   PubMed Web of Science ®Google Scholar
• . Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39(6):1901–1910
   PubMed Web of Science ®Google Scholar
• . Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870
   PubMed Web of Science ®Google Scholar
• . Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263–272
   PubMed Web of Science ®Google Scholar
• . Ogilvie IM, Newton N, Weiner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–645.e4
   PubMed Web of Science ®Google Scholar
• . Kowey PR, Reiffel JA, Myerburg R, ; AFFECTS Scientific Advisory Committee and Investigators. Warfarin and aspirin use in atrial fibrillation among practicing cardiologists (from the AFFECTS Registry). Am J Cardiol. 2010;105(8):1130–1134
   PubMedGoogle Scholar
• . Ansell JE. Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management. Semin Vasc Med. 2003;3(3):261–270
   Google Scholar
• . Fang MC, Chang Y, Hylek EM, . Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Am Intern Med. 2004;141(10):745–752
   Google Scholar
• . Gage BF, Film SD, White RH. Management and dosing of warfarin therapy. Am J Med. 2000;109(6):481–488
   PubMed Web of Science ®Google Scholar
• . Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011
   Google Scholar
• . Schwamm LH, Reeves MJ, Pan W, . Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation. 2010;121(13):1492–1501
   PubMed Web of Science ®Google Scholar
• . Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–685
   PubMedGoogle Scholar
• . Lane D, Lip GY. Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment. Age Ageing. 2005;34(1):1–3
   Google Scholar
• . Camm AJ, Kirchhof P, Lip GY, ; European Heart Rhythm Associatio; European Association for Cardio-Thoracic Surgeryn. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429
   PubMed Web of Science ®Google Scholar
• . You JJ, Singer DE, Howard PA, ; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( suppl 2):e531S–e575S
   PubMed Web of Science ®Google Scholar
• . Wann LS, Curtis AB, January CT, ; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guidelines): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(1):104–123
   PubMed Web of Science ®Google Scholar
• . Rivaroxaban [package insert]. New Brunswick, NJ: Janssen Pharmaceuticals, Inc; 2011
   Google Scholar
• . Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2011
   Google Scholar
• . FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation [press release]. Pfizer Inc website. http://www.pfizer.com/news/press_releases/pfizer_press_release_archive.jsp?guid=20111129006025en&source=2011&page=2. Accessed December 6, 2011
   Google Scholar
• . Becattini C, Lignani A, Agnelli G. New anticoagulants for the prevention of venous thromboembolism. Drug Des Devel Ther. 2010;4:49–60
   PubMed Web of Science ®Google Scholar
• . Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386–399
   PubMed Web of Science ®Google Scholar
• . Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115(1):15–20
   PubMed Web of Science ®Google Scholar
• . Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin. J Clin Pharmacol. 2006;46(9):981–990
   PubMed Web of Science ®Google Scholar
• . Raghavan N, Frost CE, Yu Z, . Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74–81
   PubMed Web of Science ®Google Scholar
• . Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost. 2009;35(5):515–524
   Google Scholar
• . Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010;103(3):572–585
   Web of Science ®Google Scholar
• . van Ryn J, Stangier J, Haertter S, . Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127
   PubMed Web of Science ®Google Scholar
• . Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis. 2010;29(2):182–191
   Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–1876
   PubMed Web of Science ®Google Scholar
• . Ezekowitz MD, Connolly S, Parekh A, . Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157(5):805–810.e2
   PubMed Web of Science ®Google Scholar
• . Wallentin L, Yusuf S, Ezekowitz MD, ; RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–983
   PubMed Web of Science ®Google Scholar
• . Eikelboom JW, Wallentin L, Connolly SJ, . Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Borris LC, Friedman RJ, ; RECORD 1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775
   PubMed Web of Science ®Google Scholar
• . Kakkar AK, Brenner B, Dahl OE, ; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–39
   PubMed Web of Science ®Google Scholar
• . Lassen MR, Ageno W, Borris LC, ; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–2786
   PubMed Web of Science ®Google Scholar
• . Turpie AG, Lassen MR, Davidson BL, ; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673–1680
   PubMed Web of Science ®Google Scholar
• . Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, ; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817
   PubMed Web of Science ®Google Scholar
• . ESC: Novel drug beats aspirin in Afib patients, www.medpagetoday.com/meetingcoverage/ESCcongress/21974. Published August 31, 2010. Accessed September 3, 2010
   Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992
   PubMed Web of Science ®Google Scholar
• . Staud F, Ceckova M, Micuda S, Pavek P. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol. 2010;596:199–222
   PubMedGoogle Scholar
• . US Food and Drug Administration. Clinical review for NDA 022-512 Pradaxa (dabigatran). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularan-drenaldrugsadvisorycommittee/UCM226011.pdf. Accessed September 27, 2010
   Google Scholar
• . Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292–303
   PubMed Web of Science ®Google Scholar
• . European Medicines Agency. Pradaxa [package insert]. Ingelheim am Rhein, Germany: Boehringer Ingelheim Pharma GmbH & Co. KG; 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_product_information/human/000829/WC500041059.pdf. Accessed August 25, 2010
   Google Scholar
• . Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579
   PubMed Web of Science ®Google Scholar
• . European Medicines Agency. Xarelto [package insert]. Leverkusen, Germany: Bayer Pharma AG; 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_product_information/human/000944/WC500057108.pdf. Accessed December 11, 2012
   Google Scholar
• . Roser-Jones C, Becker RC. Apixaban: an emerging oral factor Xa inhibitor. J Thromb Thrombolysis. 2010;29(1):141–146
   Google Scholar
• . Wang L, Zhang D, Raghavan N, . In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448–458
   PubMed Web of Science ®Google Scholar
• . Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867
   PubMed Web of Science ®Google Scholar